MHMagnus Husberg

Magnus Husberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Magnus Husberg has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Testning med GMS560-panel eller ASA till alla? : En hälsoekonomisk analys av postoperativ ASA-behandling av kolorektalcancerpatienter

    by Lars Bernfort, Magnus Husberg

    Kolorektalcancer är en av de vanligaste cancerformerna, som dessutom blir allt vanligare i yngre åldrar. Postoperativ behandling med acetylsalicylsyra (ASA) har visat sig minska risken för recidiv för en subgrupp av patienterna. Den bevisade recidivminskande effekten av ASA gäller patienter (stadium I-III rektalcancer och stadium II-III koloncancer) med mutation i PI3K-signalvägen, vilka utgör cirka 37% av patienterna.För att ta reda på vilka patienter som har denna mutation i PI3K-signalvägen kan testning göras med GMS560-panel. Eftersom testning med GMS560-panel är både tids- och resurskrävande har frågan väckts om huruvida man ska behandla alla patienter med ASA postoperativt, dvs. utan att tillämpa testning med GMS560-panel.I denna rapport jämförs i en hälsoekonomisk analys följande alternativ:Genom testning med GMS560-panel identifiera patienter med mutation i PI3K-signalvägen och behandla dessa med ASA postoperativt.Behandla alla patienter (stadium I-III rektalcancer och stadium II-III koloncancer) med ASA postoperativt.Eftersom de (37%) patienter som har recidivminskande effekt av postoperativ behandling med ASA får behandlingen i båda alternativen så finns ingen skillnad vad gäller recidiv. Skillnaderna mellan alternativen består i dels kostnaden för testning med GMS560-panel, dels den ökade risk för biverkningar som följer av att behandla alla patienter med ASA. Frågan är alltså om värdet av att undvika onödiga biverkningar (kostnader och inverkan på livskvalitet) uppväger kostnaden för testning med GMS560-panel. Våra resultat tyder på att så inte är fallet, dvs. att kostnaden för GMS560-panel är för hög för att uppväga effekterna av ökade biverkningar.Risken för allvarliga GI-blödningar, med och utan ASA, är en osäker variabel som varierats i en känslighetsanalys. Oavsett variationer i denna risk, och variationer i behandlingstid med ASA samt analysens uppföljningstid så kvarstår faktum att testning med GMS560-panel är för kostsam för att motiveras av mindre biverkningar. Utvecklingen går mot lägre kostnad för testning med GMS560-panel, en kostnadsminskning som skulle behöva vara avsevärd för att testningen ska kunna motiveras ur ett hälsoekonomiskt perspektiv.Colorectal cancer is one of the most common types of cancer, and its incidence is increasing among younger individuals. Postoperative treatment with acetylsalicylic acid (ASA) has been shown to reduce the risk of recurrence for a subgroup of patients. The proven recurrence‑reducing effect of ASA applies to patients (stage I–III rectal cancer and stage II–III colon cancer) with a mutation in the PI3K signaling pathway, who constitute approximately 37% of patients. To determine which patients carry this mutation in the PI3K signaling pathway, testing can be performed using the GMS560 panel. Since testing with the GMS560 panel is both time‑ and resource‑intensive, the question has been raised whether all patients should receive postoperative ASA treatment, i.e., without applying GMS560 panel testing. This report compares the following alternatives in a health economic analysis: Identifying patients with a PI3K pathway mutation through GMS560 panel testing and treating these patients with postoperative ASA. Treating all patients (stage I–III rectal cancer and stage II–III colon cancer) with postoperative ASA. Since the 37% of patients who benefit from postoperative ASA treatment receive it in both alternatives, there is no difference in recurrence outcomes. The differences between the alternatives lie in the cost of GMS560 panel testing and the increased risk of side effects resulting from treating all patients with ASA. The question, therefore, is whether the value of avoiding unnecessary side effects (costs and impact on quality of life) outweighs the cost of GMS560 panel testing. Our results indicate that this is not the case; the cost of the GMS560 panel is too high to offset the effects of increased side effects. The risk of severe GI bleeding, with and without ASA, is an uncertain variable that was varied in a sensitivity analysis. Regardless of variations in this risk, as well as variations in ASA treatment duration and the analysis follow‑up period, the conclusion remains that GMS560 panel testing is too costly to be justified by the reduction in side effects. The trend is towards lower costs for testing with the GMS560 panel, a cost reduction that would need to be significant for testing to be justified from a health economic perspective.

  • Implementering av nya läkemedelsrekommendationer vid hjärtsvikt : SIQ-HF studien Oktober 2025

    by Lars-Åke Levin, Lars Bernfort, Michaela Eklund, Magnus Husberg

    I denna rapport beskrivs utvecklingen av läkemedelsbehandling vid hjärtsvikt till följd av de uppdaterade behandlingsrekommendationer som publicerades den 14 januari 2022. Enligt dessa rekommendationer ska hjärtsviktspatienter med nedsatt vänsterkammarfunktion (HFrEF) behandlas med läkemedel från fyra läkemedelsgrupper, så kallad kvadrupelbehandling. För hjärtsviktspatien-ter med måttligt nedsatt vänsterkammarfunktion (HFmrEF) ska kvadrupel-behandling övervägas. Hjärtsviktspatienter med bevarad vänsterkammar-funktion (HFpEF) ska behandlas utifrån symtom och bör i normalfallet inte ges kvadrupelbehandling.Våra registerbaserade analyser visar att läkemedelsbehandlingen av hjärt-sviktspatienter har genomgått en tydlig förändring mellan januari 2022 och april 2025. Andelen patienter som någon gång provat kvadrupelbehandling har ökat från 5% till drygt 30%. För patienter med underdiagnosen HFrEF är motsvarande siffra drygt 40%. Ökningen av kvadrupelbehandling består till stor del av en ökning av den senast tillkomna läkemedelsklassen SGLT2-hämmare, som är indicerat för alla hjärtsviktspatienter, inklusive de med HFpEF. Andelen incidenta patienter som behandlas med SGLT2-hämmare har ökat från cirka 15% i januari 2022 till cirka 58% i april 2025. För patienter med HFrEF är motsvarande siffror ungefär 35% och 81%.Generellt har vi sett att patienter med en specificerad underdiagnos har större sannolikhet att få kvadrupelbehandling än de som inte fått det, även om underdiagnosen var HFpEF. Detta beror sannolikt på en tidseffekt, då specificerad diagnosticering har ökat markant sedan publiceringen av behandlingsrekommendationerna. En annan möjlig förklaring är att vårdgivare som är bra på att sätta en specifik underdiagnos också är de som är mest benägna att följa nya behandlingsriktlinjer.Användningen av både kvadrupelbehandling och SGLT2-hämmare är högre bland män än bland kvinnor och minskar med stigande ålder. Dessa skillnader kan delvis förklaras av mindre användning bland patienter med HFpEF, som både är äldre och har en större andel kvinnor än övriga underdiagnoser.Även om användningen av kvadrupelbehandling tydligt har ökat över tid, kvarstår stora regionala skillnader. I januari 2025 varierade andelen incidenta patienter som fått kvadrupelbehandling mellan 17% (Region Västmanland) och 33% (Region Blekinge). Motsvarande siffror för SGLT2-hämmare var mellan cirka 47% (Region Västmanland) och 71% (Region Gotland).Implementeringen av behandlingsrekommendationerna för patienter med hjärtsvikt har varit tämligen framgångsrik, med en markant ökning av andelen patienter som erhåller rekommenderad behandling. Det finns dock utrymme för förbättringar, vilket inte minst framgår av de stora regionala variationerna.This report describes the development of drug treatment for heart failure following the updated treatment recommendations published on January 14, 2022. According to these recommendations, heart failure patients with reduced left ventricular function (HFrEF) should be treated with medications from four groups, known as quadruple therapy. For heart failure patients with moderately reduced left ventricular function (HFmrEF), quadruple therapy should be considered. Heart failure patients with preserved left ventricular function (HFpEF) should be treated based on symptoms and generally should not receive quadruple therapy.Our registry-based analyses show that the drug treatment of heart failure patients has undergone significant changes between January 2022 and April 2025. The proportion of patients who have tried quadruple therapy has increased from 5% to above 30%. For patients with the HFrEF sub-diagnosis, the corresponding Figure is just over 40%. The increase in quadruple therapy is largely due to the increased use of the latest drug class, SGLT2 inhibitors, which are indicated for all heart failure patients, including those with HFpEF. The proportion of incident patients treated with SGLT2 inhibitors has increased from approximately 15% in January 2022 to approximately 58% in April 2025. For patients with HFrEF, the corresponding Figures are 35% and 81%.Generally, we have seen that patients with a specified sub-diagnosis are more likely to receive quadruple therapy than those who have not, even if the sub-diagnosis was HFpEF. This is likely due to a time effect, as specified diagnosis has increased significantly since the publication of the treatment recommendations. Another possible explanation is that healthcare providers who are good at making specific sub-diagnoses are also those most likely to follow new treatment guidelines.The use of both quadruple therapy and SGLT2 inhibitors is higher among men than among women and decreases with increasing age. These differences can partly be explained by lower usage among patients with HFpEF, who are older and have a higher proportion of women than other sub-diagnoses.Although the use of quadruple therapy has clearly increased over time, significant regional differences remain. In January 2025, the proportion of incident patients who received quadruple therapy varied between 17% (Region Västmanland) and 33% (Region Blekinge). The corresponding Figures for SGLT2 inhibitors were between 47% (Region Västmanland) and 71% (Region Gotland).The implementation of treatment recommendations for heart failure patients has been quite successful, with a marked increase in the proportion of patients receiving recommended treatment. However, there is...

  • Open Access

    Implementering av nya läkemedelsrekommendationer vid hjärtsvikt

    by Lars-Åke Levin, Lars Bernfort, Michaela Eklund, Magnus Husberg

    I denna rapport beskrivs utvecklingen av läkemedelsbehandling vid hjärtsvikt till följd av de uppdaterade behandlingsrekommendationer som publicerades den 14 januari 2022. Enligt dessa rekommendationer ska hjärtsviktspatienter med nedsatt vänsterkammarfunktion (HFrEF) behandlas med läkemedel från fyra läkemedelsgrupper, så kallad kvadrupelbehandling. För hjärtsviktspatien-ter med måttligt nedsatt vänsterkammarfunktion (HFmrEF) ska kvadrupelbehandling övervägas. Hjärtsviktspatienter med bevarad vänster-kammarfunktion (HFpEF) ska behandlas utifrån symtom och bör i normalfallet inte ges kvadrupelbehandling.Våra registerbaserade analyser visar att läkemedelsbehandlingen av hjärt-sviktspatienter har genomgått en tydlig förändring mellan januari 2022 och september 2024. Andelen patienter som någon gång provat kvadrupel-behandling har ökat från 5% till 30%. För patienter med underdiagnosen HFrEF är motsvarande siffra drygt 40%. Ökningen av kvadrupelbehandling består till stor del av en ökning av den senast tillkomna läkemedelsklassen SGLT2-hämmare, som är indicerat för alla hjärtsviktspatienter, inklusive de med HFpEF. Andelen incidenta patienter som behandlas med SGLT2-hämmare har ökat från cirka 15% i januari 2022 till cirka 57% i september 2024. För patienter med HFrEF är motsvarande siffror ungefär 35% och 80%.Generellt har vi sett att patienter med en specificerad underdiagnos har större sannolikhet att få kvadrupelbehandling än de som inte fått det, även om underdiagnosen var HFpEF. Detta beror sannolikt på en tidseffekt, då specificerad diagnosticering har ökat markant sedan behandlingsriktlinjernas publicering. En annan möjlig förklaring är att vårdgivare som är bra på att sätta en specifik underdiagnos också är de som är mest benägna att följa nya behandlingsriktlinjer.Användningen av både kvadrupelbehandling och SGLT2-hämmare är högre bland män än bland kvinnor och minskar med stigande ålder. Dessa skillnader kan delvis förklaras av mindre användning bland patienter med HFpEF, som både är äldre och har en större andel kvinnor än övriga underdiagnoser.Även om användningen av kvadrupelbehandling tydligt har ökat över tid, kvarstår stora regionala skillnader. I september 2024 varierade andelen inci-denta patienter som fått kvadrupelbehandling mellan 13% (Region Västmanland) och 32% (Region Gävleborg). Motsvarande siffror för SGLT2-hämmare var mellan cirka 38% (Region Västmanland) och 63% (Region Gävleborg).Implementeringen av behandlingsrekommendationerna för patienter med hjärtsvikt har varit tämligen framgångsrik, med en markant ökning av andelen patienter som erhåller rekommenderad behandling. Det finns dock utrymme för förbättringar, vilket inte minst framgår av de stora regionala variationerna.

  • Open Access

    Physical and mental disability is evident 8 years after diagnosis in early rheumatoid arthritis despite contemporary medication and non-pharmacological interventions

    by Ingrid Thyberg, Magnus Husberg, Alf Kastbom

    Introduction: Early interventions are known to reduce disease activity and physical disability in rheumatoid arthritis (RA), but less is known about mental health, especially in the era of early active pharmacotherapy. Consequently, we compared long-term physical and mental disability in an early RA cohort (1996–1998) with a later cohort (2006–2008). Methods: We compared 320 patients from our project Early Intervention in RA (1996–1998) (TIRA-1) with 463 patients from TIRA-2 (2006–2008). During the 8-year follow-up, pharmacotherapy and multi-professional interventions were offered according to guidelines. Disease Activity Score (DAS28), prescribed disease-modifying antirheumatic drugs (DMARDs), Health Assessment Questionnaire (HAQ), and Short Form Health Survey (SF-36) were registered yearly. Results: Significantly more patients were prescribed DMARDs in TIRA-2 than in TIRA-1, and initial improvements were seen for DAS28 and disability in both cohorts. At follow-up, TIRA-2 patients reported less physical disability (HAQ) and less mental disability (SF-36) than TIRA-1 patients. Despite improvements, 32% of the women and 21% of the men in the TIRA-2 cohort reported considerable disability (HAQ ≥ 1) at the 8-year follow-up. Conclusions: Despite improvements in our contemporarily treated TIRA-2 cohort, physical and mental disability was evident 8 years after diagnosis, especially among women. These results suggest a forthcoming need for person-centered non-pharmacological rehabilitation programs to optimize physical and mental function and to improve participation in daily life in RA. Also, the results highlight the need for developing new interventions directed at reducing disability. Key Points• Physical and mental disability is still considerable in contemporarily treated RA.• Interventions specifically aimed to reduce these disabilities need to be further developed.• Patients with severe disability need to be identified in clinical settings and offered person-centered rehabilitation.


  • Open Access

    Cost‐effectiveness of root canal treatment compared with tooth extraction in a Swedish Public Dental Service: A prospective controlled cohort study

    by Emma Wigsten, Thomas Kvist, Magnus Husberg, Endo Re Co, Thomas Davidson

    Objectives: To evaluate the cost‐effectiveness of root canal treatment (RCT) compared with a tooth extraction in a general dental practice setting, with reference to cost per quality‐adjusted life‐year (QALY) gained over 1 year.Material and Methods: This is a prospective controlled cohort study based on patients either starting RCT or undergoing extraction at one of six Public Dental Service clinics in the county of Västra Götaland, Sweden. From a total of 65 patients, 2 comparable groups were formed: 37 started RCT and 28 underwent extraction. A societal perspective was used for the cost calculations. QALYs were estimated, based on the EQ‐5D‐5L given to the patients at their first treatment appointment and then after 1, 6, and 12 months.Results: The total mean cost of RCT ($689.1) was higher than for extraction ($280.1). For those patients whose extracted tooth was replaced, the costs were even higher ($1245.5). There were no significant intergroup differences in QALYs, but a significant improvement in health state values in the tooth‐preserving group.Conclusions: In the short term, extraction was cost‐effective compared with preserving a tooth with RCT. However, the potential need for future replacement of the extracted tooth, by an implant, fixed prosthesis, or removable partial dentures, may change the calculation in favor of RCT.


  • Open Access

    Cost-effectiveness of different exercise intensities during oncological treatment in the Phys-Can RCT

    by Anna-Karin Ax, Magnus Husberg, Birgitta Johansson, Ingrid Demmelmaier, Sveinung Berntsen, Katarina Sjövall, Sussanne Börjeson, Karin Nordin, Thomas Davidson

    Cost-effectiveness is important in the prioritisation between interventions in health care. Exercise is cost-effective compared to usual care during oncological treatment; however, the significance...


  • Open Access

    Long-term resource utilisation and associated costs of exercise during (neo)adjuvant oncological treatment: the Phys-Can project

    by Anna-Karin Ax, Magnus Husberg, Birgitta Johansson, Ingrid Demmelmaier, Sveinung Berntsen, Katarina Sjövall, Sussanne Börjeson, Karin Nordin, Thomas Davidson

    Exercise during oncological treatment is beneficial to patient health and can counteract the side effects of treatment. Knowledge of the societal costs associated with an exercise intervention, how...


  • Open Access

    Long-Term Cost-Effectiveness through the Dental-Health FRAMM Guideline for Caries Prevention

    by Thomas Davidson, Eva-Karin Bergström, Magnus Husberg, Ulla Moberg Sköld

    A guideline called FRAMM, which is an acronym in Swedish for the most important parts of this guideline, namely “fluoride”, “advice”, “arena”, “motivation” and “diet”, was implemented in 2008 in the Västra Götaland Region in Sweden. This guideline included fluoride varnish applications performed at school twice a year at six-monthly intervals for all 12- to 15-year-olds, together with lessons on oral health. The aim of this analysis was to estimate the long-term cost-effectiveness, using prognostic calculations, of the FRAMM Guideline for 12- to 15-year-olds, compared with routine care, until the participants were 23 years old. A cost-effectiveness analysis was performed from a health care perspective, based on four years of verified data and seven years of prognosis. Data from FRAMM were combined with cost data from price lists in Sweden. The cost-effectiveness was analyzed by relating the difference in costs to the difference in the number of approximal surfaces with fillings and/or dentin lesions (DFSa). The analysis shows that FRAMM was considered dominant compared to the controls in all alternative scenarios, hence costs were prognosed to be lowered and outcomes were prognosed to be improved. A dental health program like the FRAMM Guideline with fluoride varnish during the caries risk period from 12 to 15 years is predicted to be cost-effective in the longer perspective. To further study the actual long-term caries increment after a preventive dental health program would be of great interest to verify these results.


  • Open Access

    Cost-effectiveness of comprehensive geriatric assessment at an ambulatory geriatric unit based on the AGe-FIT trial

    by Martina Lundqvist, Jenny Alwin, Martin Henriksson, Magnus Husberg, Per Carlsson, Anne W. Ekdahl

    Older people with multi-morbidity are increasingly challenging for today’s healthcare, and novel, cost-effective healthcare solutions are needed. The aim of this study was to assess the cost-effectiveness of comprehensive geriatric assessment (CGA) at an ambulatory geriatric unit for people ≥75 years with multi-morbidity. The primary outcome was the incremental cost-effectiveness ratio (ICER) comparing costs and quality-adjusted life years (QALYs) of a CGA strategy with usual care in a Swedish setting. Outcomes were estimated over a lifelong time horizon using decision-analytic modelling based on data from the randomized AGe-FIT trial. The analysis employed a public health care sector perspective. Costs and QALYs were discounted by 3% per annum and are reported in 2016 euros. Compared with usual care CGA was associated with a per patient mean incremental cost of approximately 25,000 EUR and a gain of 0.54 QALYs resulting in an ICER of 46,000 EUR. The incremental costs were primarily caused by intervention costs and costs associated with increased survival, whereas the gain in QALYs was primarily a consequence of the fact that patients in the CGA group lived longer. CGA in an ambulatory setting for older people with multi-morbidity results in a cost per QALY of 46,000 EUR compared with usual care, a figure generally considered reasonable in a Swedish healthcare context. A rather simple reorganisation of care for older people with multi-morbidity may therefore cost effectively contribute to meet the needs of this complex patient population. The trial was retrospectively registered in clinicaltrial.gov, NCT01446757 . September, 2011.


  • Open Access

    Acute care of severely frail elderly patients in a CGA-unit is associated with less functional decline than conventional acute care

    by Niklas Ekerstad, Synneve Dahlin-Ivanoff, Sten Landahl, Göran Östberg, Maria Johansson, David Andersson, Magnus Husberg, Jenny Alwin, Björn W Karlson

    Background: A high percentage of individuals treated in specialized acute care wards are frail and elderly. Our aim was to study whether the acute care of such patients in a comprehensive geriatric assessment (CGA) unit is superior to care in a conventional acute medical care unit when it comes to activities of daily living (ADLs), frailty, and use of municipal help services. Patients and methods: A clinical, prospective, controlled trial with two parallel groups was conducted in a large county hospital in West Sweden and included 408 frail elderly patients, age 75 or older (mean age 85.7 years; 56% female). Patients were assigned to the intervention group (n=206) or control group (n=202). Primary outcome was decline in functional activity ADLs assessed by the ADL Staircase 3 months after discharge from hospital. Secondary outcomes were degree of frailty and use of municipal help services. Results: After adjustment by regression analyses, treatment in a CGA unit was independently associated with lower risk of decline in ADLs [odds ratio (OR) 0.093; 95% confidence interval (CI) 0.052–0.164; P PP=0.0001). There was no significant difference between the groups in increased use of municipal help services (OR 0.682; 95% CI 0.395–1.178; P=0.170). Conclusion: Acute care of frail elderly patients in a CGA unit was independently associated with lesser loss of functional ability and lesser increase in frailty after 3 months.